Research graph
References from Increased risk of chronic kidney disease and mortality in a cohort of people diagnosed with metabolic dysfunction associated steatotic liver disease with hepatic fibrosis. Local targets link to admitted publications; unresolved targets remain external evidence.
The prevalence and incidence of NAFLD WORLDWIDE: A systematic review and meta-analysis
10.1016/s2468-1253(22)00165-0 · 2022 · External reference
Global prevalence of chronic kidney disease–a systematic review and meta-analysis.
2016 · External reference
NAFLD and increased risk of cardiovascular disease: clinical associations, pathophysiological mechanisms and pharmacological implications
10.1136/gutjnl-2020-320622 · 2020 · External reference
Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention.
10.1038/nrgastro.2017.109 · 2018 · External reference
Nonalcoholic Fatty Liver Disease: Predictors of Nonalcoholic Steatohepatitis and Liver Fibrosis in the Severely Obese
10.1053/gast.2001.25540 · 2001 · External reference
Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016–2030,
10.1016/j.jhep.2018.05.036 · 2018 · External reference
Unresolved reference
2022 · External reference
Non-alcoholic fatty liver disease (NAFLD) is associated with an increased incidence of extrahepatic cancer
2022 · External reference
Extrahepatic morbidities and mortality of NAFLD: an umbrella review of meta-analyses
10.1111/apt.17165 · 2022 · External reference
Association of Non-alcoholic Fatty Liver Disease with Chronic Kidney Disease: A Systematic Review and Meta-analysis.
10.1371/journal.pmed.1001680 · External reference
Nonalcoholic fatty liver disease is independently associated with an increased incidence of chronic kidney disease in patients with type 1 diabetes
10.2337/dc13-2704 · 2014 · External reference
Non-alcoholic Fatty Liver Disease and Chronic Kidney Disease in Koreans Aged 50 Years or Older.
10.4082/kjfm.2013.34.3.199 · 2013 · External reference
Implications of worse renal dysfunction and medical comorbidities in patients with NASH undergoing liver transplant evaluation: impact on MELD and more
10.1111/j.1399-0012.2011.01497.x · External reference
Impact of non-alcoholic fatty liver disease on microalbuminuria in patients with prediabetes and diabetes
10.1111/j.1445-5994.2009.01979.x · 2010 · External reference
Non-alcoholic fatty liver disease is independently associated with an increased prevalence of chronic kidney disease and retinopathy in type 1 diabetic patients
10.1007/s00125-010-1720-1 · 2010 · External reference
Non-alcoholic fatty liver disease is independently associated with an increased prevalence of chronic kidney disease and proliferative/laser-treated retinopathy in type 2 diabetic patients
10.1007/s00125-007-0897-4 · 2008 · External reference
Development of chronic kidney disease in patients with non-alcoholic fatty liver disease: A cohort study
10.1016/j.jhep.2017.08.024 · 2017 · External reference
Unresolved reference
2023 · External reference
NAFLD as a driver of chronic kidney disease
10.1016/j.jhep.2020.01.013 · 2020 · External reference
NAFLD and Chronic Kidney Disease
10.3390/ijms17040562 · 2016 · External reference
Intelligent liver function testing (ilft): A trial of automated diagnosis and staging of liver disease in primary care.
10.1016/j.jhep.2019.05.033 · 2019 · External reference
Scottish Government Health Board Data: Tayside
External reference
A multi-society Delphi consensus statement on new fatty liver disease nomenclature [published online ahead of print, 2023 Jun 24]
2023 · External reference
KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease
2013 · External reference
Unresolved reference
2010 · External reference
Renal considerations in angiotensin converting enzyme inhibitor therapy
10.1161/hc4101.096153 · 2001 · External reference
Diuretics for people with chronic kidney disease.
2017 · External reference
Protecting and using patient information: the role of the Caldicott Guardian.
10.7861/clinmedicine.4-3-246 · 2004 · External reference
UK Policy Framework for defining Health and Social Care Research
2017 · External reference
On the choice of timescale for other cause mortality in a competing risk setting using flexible parametric survival models
10.1002/bimj.202100254 · 2022 · External reference
Use of alternative time scales in Cox proportional hazard models: implications for time-varying environmental exposures
10.1002/sim.5347 · 2012 · External reference
Longitudinal outcomes associated with metabolic dysfunction-associated steatotic liver disease: A meta-analysis of 129 studies’
2023 · External reference
Comorbidities Are Associated with Fibrosis in NAFLD Subjects: A Nationwide Study (NASH-CO Study).
10.1007/s10620-021-07032-z · 2022 · External reference
Prospective study of outcomes in adults with nonalcoholic fatty liver disease
10.1056/nejmoa2029349 · 2021 · External reference
MASLD, hepatic steatosis and fibrosis are associated with the prevalence of chronic kidney disease and retinopathy in adults with type 1 diabetes mellitus
10.1016/j.diabet.2023.101497 · 2024 · External reference
Metabolic dysfunction-associated steatotic liver disease and risk of cardiovascular disease
2023 · External reference
Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes
10.1002/hep.28431 · 2016 · External reference
Clinical epidemiology and disease burden of nonalcoholic fatty liver disease
10.3748/wjg.v23.i47.8263 · 2017 · External reference
Changing from NAFLD TO MASLD: The new definition can more accurately identify individuals at higher risk for diabetes
2023 · External reference
Hepatorenal syndrome: pathophysiology, diagnosis, and management
10.1136/bmj.m2687 · 2020 · External reference
Overlooked subclinical portal hypertension in non-cirrhotic NAFLD: Is it real and how to measure it?
10.1016/j.jhep.2021.09.029 · 2021 · External reference
Glomerular hyperfiltration.
10.1038/s41581-022-00559-y · 2022 · External reference
Glomerular Hyperfiltration is a new marker of fibrosis severity in non-cirrhotic NAFLD
10.1016/j.dld.2023.01.094 · 2023 · External reference
Central obesity associates with renal hyperfiltration in the non-diabetic general population: a cross-sectional study.
10.1186/s12882-016-0386-4 · 2016 · External reference
The impact of non-alcoholic fatty liver disease and liver fibrosis on adverse clinical outcomes and mortality in patients with chronic kidney disease: a prospective cohort study using the UK Biobank
10.1186/s12916-023-02891-x · 2023 · External reference
Nonalcoholic fatty liver disease accelerates kidney function decline in patients with chronic kidney disease: a cohort study
10.1038/s41598-018-23014-0 · 2018 · External reference
Metabolic-associated fatty liver disease increases the risk of end-stage renal disease in patients with biopsy-confirmed diabetic nephropathy: a propensity-matched cohort study
10.1007/s00592-022-01978-w · 2023 · External reference
Increased risk of mortality by fibrosis stage in nonalcoholic Fatty Liver Disease: Systematic review and meta‐analysis
10.1002/hep.29085 · 2017 · External reference
Patterns of multi-morbidity and prediction of hospitalisation and all-cause mortality in advanced age.
10.1093/ageing/afx184 · 2018 · External reference
Global, regional, and national burden of chronic kidney disease, 1990–2017: A systematic analysis for the global burden of disease study 2017
10.1016/s0140-6736(20)30045-3 · 2020 · External reference
The impact of chronic kidney disease on developed countries from a health economics perspective: A systematic scoping review.
10.1371/journal.pone.0230512 · 2020 · External reference
The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review.
10.1097/hep.0000000000000004 · 2023 · External reference
A prospective study on the prevalence of NAFLD, advanced fibrosis, cirrhosis and hepatocellular carcinoma in people with type 2 diabetes
10.1016/j.jhep.2022.11.010 · 2023 · External reference
Population based screening for chronic kidney disease: cost effectiveness study
10.1136/bmj.c5869 · 2010 · External reference
Renin-Angiotensin System Inhibitors and Kidney and Cardiovascular Outcomes in Patients With CKD: A Bayesian Network Meta-analysis of Randomized Clinical Trials
10.1053/j.ajkd.2015.10.011 · 2016 · External reference
Modelling NAFLD disease burden in four Asian regions—2019–2030.
10.1111/apt.15673 · External reference
Healthcare and socioeconomic costs of NAFLD: A global framework to navigate the uncertainties
10.1016/j.jhep.2023.01.026 · 2023 · External reference
AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease
10.1097/hep.0000000000000323 · 2023 · External reference
Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease
10.1016/j.jhep.2015.11.004 · 2016 · External reference
Routinely collected data and comparative effectiveness evidence: promises and limitations.
10.1503/cmaj.150653 · 2016 · External reference
Type 2 Diabetes; Diagnosis in adults (NICE guidelines).
2023 · External reference
